Acquisition of cancer-associated mutational change is fundamental to thyroid carcinogenesis, however, up to 30% of thyroid follicular lining cell malignancies can lack detection of mutational change.
Our study uses a combined mutation detection and microRNA (miRNA) classifier determination to evaluate the role of mutational heterogeneity in thyroid nodules.
Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.
©2023 Interpace Biosciences®. All Rights Reserved.
Interpace Diagnostics®, LLC is a registered trademark and subsidiary of Interpace Biosciences, Inc.
